Kairos Pharma (NYSEAMERICAN:KAPA) Earns Buy Rating from D. Boral Capital

Kairos Pharma (NYSEAMERICAN:KAPA)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $9.00 price target on the stock.

Kairos Pharma Price Performance

KAPA opened at $0.95 on Tuesday. Kairos Pharma has a 12 month low of $0.40 and a 12 month high of $3.25. The stock has a market cap of $19.77 million, a P/E ratio of -2.84 and a beta of 2.02. The stock’s 50 day moving average price is $1.30 and its 200 day moving average price is $0.97.

Hedge Funds Weigh In On Kairos Pharma

A hedge fund recently bought a new stake in Kairos Pharma stock. XTX Topco Ltd purchased a new stake in shares of Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 62,746 shares of the company’s stock, valued at approximately $44,000. XTX Topco Ltd owned approximately 0.31% of Kairos Pharma at the end of the most recent quarter.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.